President Donald Trump announced Heidi Overton as his pick for FDA commissioner, setting up a leadership change for the US drug regulator. Multiple reports and the administration’s announcement describe Overton as a medical doctor with additional research and policy background. The nomination is expected to proceed to Senate review, and it arrives after the agency operated without a permanent commissioner following Marty Makary’s resignation earlier in the year. Interim leadership has been in place while policy and regulatory direction have been under scrutiny. Biopharma stakeholders are likely to focus on Overton’s approach to drug review and regulatory flexibility, particularly after recent periods of unusual leadership turnover. Specific policy priorities and how they align with White House and HHS direction may become clearer following confirmation. The nomination also has potential implications for how the FDA manages emerging regulatory topics, including generative AI-enabled medical devices and broader oversight updates.